Skip to content

Replimune Group REPL Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Immunome logo
ImmunomeIMNM
CG Oncology logo
CG OncologyCGON
Erasca, Inc. logo
Erasca, Inc.ERAS

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's deferred tax assets and other non-current assets?
Replimune Group (REPL) reported deferred tax assets and other non-current assets of $1.2M in Q4 2025.
How has Replimune Group's deferred tax assets and other non-current assets changed year-over-year?
Replimune Group's deferred tax assets and other non-current assets decreased by 0.0% year-over-year, from $1.2M to $1.2M.